Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

• Jun-ichi Nishimura,
• Kiyoshi Ando,
• Masayoshi Masuko,
• Hideyoshi Noji,
• Yoshikazu Ito,
• Jiri Mayer,
• Laimonas Griskevicius,
• Christoph Bucher,
• Florian Müllershausen,
• Peter Gergely,
• Izabela Rozenberg,
• Anna Schubart,
• Raghav Chawla,
• Jean-Michel Rondeau,
• Michael Roguska,
• Igor Splawski,
• Mark T. Keating,
• Leslie Johnson,
• Rambabu Danekula,
• Morten Bagger,
• Yoko Watanabe,
• Börje Haraldsson,
• Yuzuru Kanakura

Affiliations

Jun-ichi Nishimura

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita

Kiyoshi Ando

Department of Hematology and Oncology, Tokai University, Isehara

Masayoshi Masuko

Department of Hematology, Endocrinology and Metabolism, Niigata University Medical and Dental Hospital, Niigata

Hideyoshi Noji

Department of Cardiology and Hematology, Fukushima Medical University, Fukushima

Yoshikazu Ito

Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo

Jiri Mayer

Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital and Faculty of Medicine, Brno, Czech Republic

Laimonas Griskevicius

Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Institute of Clinical Medicine, Vilnius University, Vilnius

Christoph Bucher

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Florian Müllershausen

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Peter Gergely

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Izabela Rozenberg

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Anna Schubart

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Raghav Chawla

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Jean-Michel Rondeau

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Michael Roguska

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Igor Splawski

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Mark T. Keating

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Leslie Johnson

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Rambabu Danekula

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Morten Bagger

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Yoko Watanabe

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Börje Haraldsson

Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo

Yuzuru Kanakura

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan; Sumitomo Hospital, Osaka